TP53 or Not TP53: That Is the Question

Azacitidine and venetoclax are a standard first-line regimen for patients with newly diagnosed unfit acute myeloid leukemia (AML). In a pooled subset analysis, TP53-mutated AML with poor-risk cytogenetics does not appear to benefit from the addition of venetoclax to azacitidine. This has clinical implications as these patients should be preferentially treated with alternative regimens.

Automated summary

Azacitidine and venetoclax are commonly used as first-line treatment for newly diagnosed unfit acute myeloid leukemia (AML) patients. However, in patients with TP53 mutations and poor-risk cytogenetics, the addition of venetoclax to azacitidine does not provide significant benefits. It is important to consider alternative treatment regimens for these patients.